Thais Coutinho1,2,3, Olabimpe Lamai4, Kara Nerenberg5. 1. Canadian Women's Heart Health Centre, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada. tcoutinho@ottawaheart.ca. 2. Division of Cardiac Prevention & Rehabilitation, University of Ottawa Heart Institute, Ottawa, ON, Canada. tcoutinho@ottawaheart.ca. 3. Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada. tcoutinho@ottawaheart.ca. 4. Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada. 5. Departments of Medicine, Obstetrics & Gynecology and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Abstract
PURPOSE OF THE REVIEW: Cardiovascular diseases (CVDs) are the principal killers of women. In this review, we summarize data regarding CVD and mortality after hypertensive disorders of pregnancy (HDP), and highlight clinical, research and policy needs to mitigate this risk. RECENT FINDINGS: Robust data indicate that women with HDP have substantially higher risk of future CVD, with a 3.7-fold increase in the risk of chronic hypertension, a 4.2-fold increase in the risk of heart failure, an 81% increase in the risk of stroke, and double the risk of atrial arrhythmias, coronary heart disease, and mortality when compared to women with normotensive pregnancies. Potential explanations include (1) the effect of pregnancy as a "stress test" in women destined to develop CVD, (2) mediation by conventional risk factors, (3) long-term vascular damage sustained during the preeclamptic episode, and (4) preexisting abnormalities in arterial health predisposing women to HDP, and, subsequently, CVD. Women with HDP have significantly increased risk of CVD and mortality. Risk scores including obstetric history are necessary to better estimate a woman's cardiovascular risk. In addition, comprehensive policies promoting systematic risk assessment and modification after HDP are critically needed to improve health, wellness, and survival of affected women.
PURPOSE OF THE REVIEW: Cardiovascular diseases (CVDs) are the principal killers of women. In this review, we summarize data regarding CVD and mortality after hypertensive disorders of pregnancy (HDP), and highlight clinical, research and policy needs to mitigate this risk. RECENT FINDINGS: Robust data indicate that women with HDP have substantially higher risk of future CVD, with a 3.7-fold increase in the risk of chronic hypertension, a 4.2-fold increase in the risk of heart failure, an 81% increase in the risk of stroke, and double the risk of atrial arrhythmias, coronary heart disease, and mortality when compared to women with normotensive pregnancies. Potential explanations include (1) the effect of pregnancy as a "stress test" in women destined to develop CVD, (2) mediation by conventional risk factors, (3) long-term vascular damage sustained during the preeclamptic episode, and (4) preexisting abnormalities in arterial health predisposing women to HDP, and, subsequently, CVD. Women with HDP have significantly increased risk of CVD and mortality. Risk scores including obstetric history are necessary to better estimate a woman's cardiovascular risk. In addition, comprehensive policies promoting systematic risk assessment and modification after HDP are critically needed to improve health, wellness, and survival of affected women.
Authors: R Orabona; E Sciatti; E Vizzardi; I Bonadei; A Valcamonico; M Metra; T Frusca Journal: Ultrasound Obstet Gynecol Date: 2017-01 Impact factor: 7.299
Authors: Tracey L Weissgerber; Stephen T Turner; Kent R Bailey; Thomas H Mosley; Sharon L R Kardia; Heather J Wiste; Virginia M Miller; Iftikhar J Kullo; Vesna D Garovic Journal: Atherosclerosis Date: 2013-04-18 Impact factor: 5.162
Authors: Leonie K Callaway; H David McIntyre; Gail M Williams; Jake M Najman; Debbie A Lawlor; Abdullah Mamun Journal: Aust N Z J Obstet Gynaecol Date: 2011-08-22 Impact factor: 2.100
Authors: M H Criqui; R D Langer; A Fronek; H S Feigelson; M R Klauber; T J McCann; D Browner Journal: N Engl J Med Date: 1992-02-06 Impact factor: 91.245
Authors: Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Leonelo Bautista; Maria Grazia Franzosi; Patrick Commerford; Chim C Lang; Zvonko Rumboldt; Churchill L Onen; Liu Lisheng; Supachai Tanomsup; Paul Wangai; Fahad Razak; Arya M Sharma; Sonia S Anand Journal: Lancet Date: 2005-11-05 Impact factor: 79.321
Authors: Yoav Yinon; John C P Kingdom; Ayodele Odutayo; Rahim Moineddin; Sascha Drewlo; Vesta Lai; David Z I Cherney; Michelle A Hladunewich Journal: Circulation Date: 2010-10-18 Impact factor: 29.690
Authors: Jamarius P Waller; John Aaron Howell; Hali Peterson; Eric M George; Gene L Bidwell Journal: Hypertension Date: 2021-11-01 Impact factor: 10.190
Authors: Lauren J Tanz; Jennifer J Stuart; Paige L Williams; Eric B Rimm; Stacey A Missmer; Kenneth J Mukamal; Kathryn M Rexrode; Janet W Rich-Edwards Journal: J Womens Health (Larchmt) Date: 2021-08-12 Impact factor: 3.017
Authors: Haiyan Chu; Anastasia Sacharidou; An Nguyen; Chun Li; Ken L Chambliss; Jane E Salmon; Yu-Min Shen; Julie Lo; Gustavo W Leone; Joachim Herz; David Y Hui; Denise K Marciano; Vikki M Abrahams; Bryony V Natale; Alina P Montalbano; Xue Xiao; Lin Xu; David R Natale; Philip W Shaul; Chieko Mineo Journal: Circ Res Date: 2021-08-18 Impact factor: 23.213